Bristol to present late-stage results on ulcerative colitis med ozanimod Oct. 12

• Bristol Myers Squibb (NYSE:BMY) will host a virtual investor event on Monday, October 12, at 8:00 am ET to discuss results from a Phase 3 clinical trial, True North, evaluating Zeposia (ozanimod) in patients with moderate-to-severe ulcerative colitis. In June, it announced that the study met both primary endpoints and key secondary endpoints.
• The data are being virtually presented at United European Gastroenterology Week.
• Ozanimod is an oral, once-daily selective sphingosine 1-phosphate 1 and 5 receptor modulator being developed for the treatment of autoimmune diseases. It diminishes the activity of autoreactive lymphocytes (white blood cells), which is the cause of many types of autoimmune disorders. BMY unit Celgene obtained the rights to the drug via its $7.2B acquisition of Receptos. It was approved in the U.S. in March for relapsing forms of multiple sclerosis.
• https://seekingalpha.com/news/3619333-bristol-myers-to-present-late-stage-results-on-ulcerative-colitis-med-ozanimod-october-12